Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)
PR Newswire —
SHANGHAI and BOSTON, Jan. 25, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that the first patient has been dosed in a global Phase 2b clinical trial...